BACKGROUND: We hypothesized that autophagy inhibition would enhance the anticancer efficacy of ret protooncogene-targeted therapy in medullary thyroid cancer. METHODS: Medullary thyroid cancer-1.1 and TT cells were treated with sunitinib or sorafenib in the presence or absence of everolimus, trehalose, or small interfering RNA directed against autophagy protein 5. RESULTS: Sunitinib and sorafenib each robustly induced light chain 3-II expression, indicating autophagy activation. Autophagy protein 5 silencing diminished the antiproliferative effects of sunitinib and sorafenib by 44% (P < .05) and 41% (P < .05), respectively, in medullary thyroid cancer-1.1 cells and by 43% (P < .01) and 39% (P < .05), respectively, in TT cells. In contrast, everolimus increased the antiproliferative effects of sunitinib and sorafenib by 24% (P < .01) and 27% (P < .01), respectively, in medullary thyroid cancer-1.1 cells and by 20% (P < .05) and 23% (P < .05), respectively, in TT cells. Trehalose increased the antiproliferative effects of sunitinib and sorafenib by 26% (P < .01) and 27% (P < .01), respectively, in medullary thyroid cancer-1.1 cells and by 28% (P < .05) and 29% (P < .05), respectively, in TT cells. Autophagy protein 5 silencing abrogated both everolimus- and trehalose-induced increases in tyrosine kinase inhibitor efficacy. CONCLUSION: Loss (gain) of autophagy diminishes (improves) the efficacy of sunitinib and sorafenib. Our findings suggest that autophagic activation should be combined with targeted ret protooncogene therapy for patients with advanced medullary thyroid cancer.
BACKGROUND: We hypothesized that autophagy inhibition would enhance the anticancer efficacy of ret protooncogene-targeted therapy in medullary thyroid cancer. METHODS: Medullary thyroid cancer-1.1 and TT cells were treated with sunitinib or sorafenib in the presence or absence of everolimus, trehalose, or small interfering RNA directed against autophagy protein 5. RESULTS:Sunitinib and sorafenib each robustly induced light chain 3-II expression, indicating autophagy activation. Autophagy protein 5 silencing diminished the antiproliferative effects of sunitinib and sorafenib by 44% (P < .05) and 41% (P < .05), respectively, in medullary thyroid cancer-1.1 cells and by 43% (P < .01) and 39% (P < .05), respectively, in TT cells. In contrast, everolimus increased the antiproliferative effects of sunitinib and sorafenib by 24% (P < .01) and 27% (P < .01), respectively, in medullary thyroid cancer-1.1 cells and by 20% (P < .05) and 23% (P < .05), respectively, in TT cells. Trehalose increased the antiproliferative effects of sunitinib and sorafenib by 26% (P < .01) and 27% (P < .01), respectively, in medullary thyroid cancer-1.1 cells and by 28% (P < .05) and 29% (P < .05), respectively, in TT cells. Autophagy protein 5 silencing abrogated both everolimus- and trehalose-induced increases in tyrosine kinase inhibitor efficacy. CONCLUSION: Loss (gain) of autophagy diminishes (improves) the efficacy of sunitinib and sorafenib. Our findings suggest that autophagic activation should be combined with targeted ret protooncogene therapy for patients with advanced medullary thyroid cancer.
Authors: Jerel A Fields; Jeff Metcalf; Cassia Overk; Anthony Adame; Brian Spencer; Wolfgang Wrasidlo; Jazmin Florio; Edward Rockenstein; Johnny J He; Eliezer Masliah Journal: J Neurovirol Date: 2017-01-19 Impact factor: 2.643
Authors: Lindsay DeVorkin; Matthew Hattersley; Paul Kim; Jenna Ries; Jaeline Spowart; Michael S Anglesio; Samuel M Levi; David G Huntsman; Ravi K Amaravadi; Jeffrey D Winkler; Anna V Tinker; Julian J Lum Journal: Mol Cancer Res Date: 2017-02-09 Impact factor: 5.852
Authors: Romana T Netea-Maier; Viola Klück; Theo S Plantinga; Johannes W A Smit Journal: Front Endocrinol (Lausanne) Date: 2015-02-18 Impact factor: 5.555
Authors: Justin S Gundara; JingTing Zhao; Anthony J Gill; James C Lee; Leigh Delbridge; Bruce G Robinson; Catriona McLean; Jonathan Serpell; Stan B Sidhu Journal: Cancer Med Date: 2014-12-08 Impact factor: 4.452
Authors: Theo S Plantinga; Esther van de Vosse; Angelique Huijbers; Mihai G Netea; Leo A B Joosten; Jan W A Smit; Romana T Netea-Maier Journal: PLoS One Date: 2014-04-16 Impact factor: 3.240
Authors: Nestor Prieto-Domínguez; Raquel Ordóñez; Anna Fernández; Andres García-Palomo; Jordi Muntané; Javier González-Gallego; José L Mauriz Journal: Front Pharmacol Date: 2016-06-08 Impact factor: 5.810